Asarina Pharma AB (publ) (ASAP.ST)
SEK 0.03
(-31.03%)
SEK 0.03
(-31.03%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 6.07 Million SEK | -63.95% |
| 2022 | 16.85 Million SEK | -44.48% |
| 2021 | 30.36 Million SEK | -55.54% |
| 2020 | 68.28 Million SEK | -51.19% |
| 2019 | 139.89 Million SEK | -6.48% |
| 2018 | 149.58 Million SEK | 1061.79% |
| 2017 | 12.87 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q3 | 6.07 Million SEK | -23.13% |
| 2023 Q2 | 7.9 Million SEK | 0.0% |
| 2023 Q1 | 7.9 Million SEK | -53.1% |
| 2023 FY | 6.07 Million SEK | -63.95% |
| 2023 Q4 | 6.07 Million SEK | 0.0% |
| 2022 Q4 | 16.85 Million SEK | 0.0% |
| 2022 FY | 16.85 Million SEK | -44.48% |
| 2022 Q3 | 16.85 Million SEK | -20.55% |
| 2022 Q2 | 21.21 Million SEK | -14.79% |
| 2022 Q1 | 24.89 Million SEK | -17.99% |
| 2021 FY | 30.36 Million SEK | -55.54% |
| 2021 Q4 | 30.36 Million SEK | -7.23% |
| 2021 Q3 | 32.72 Million SEK | -24.4% |
| 2021 Q1 | 51.49 Million SEK | -24.58% |
| 2021 Q2 | 43.29 Million SEK | -15.94% |
| 2020 Q3 | 77.08 Million SEK | -19.48% |
| 2020 Q1 | 122.64 Million SEK | -12.33% |
| 2020 FY | 68.28 Million SEK | -51.19% |
| 2020 Q4 | 68.28 Million SEK | -11.41% |
| 2020 Q2 | 95.73 Million SEK | -21.94% |
| 2019 Q1 | 137.23 Million SEK | -8.25% |
| 2019 Q2 | 118.05 Million SEK | -13.98% |
| 2019 FY | 139.89 Million SEK | -6.48% |
| 2019 Q4 | 139.89 Million SEK | 35.11% |
| 2019 Q3 | 103.53 Million SEK | -12.3% |
| 2018 Q2 | 14.59 Million SEK | 0.0% |
| 2018 FY | 149.58 Million SEK | 1061.79% |
| 2018 Q1 | - SEK | -100.0% |
| 2018 Q4 | 149.58 Million SEK | 1.23% |
| 2018 Q3 | 147.76 Million SEK | 912.65% |
| 2017 Q4 | 12.87 Million SEK | 0.0% |
| 2017 FY | 12.87 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 99.68% |
| AcouSort AB (publ) | 34.51 Million SEK | 82.392% |
| Active Biotech AB (publ) | 44 Million SEK | 86.189% |
| Alzinova AB (publ) | 123.18 Million SEK | 95.067% |
| Amniotics AB (publ) | 26.08 Million SEK | 76.704% |
| BioArctic AB (publ) | 1.18 Billion SEK | 99.488% |
| Camurus AB (publ) | 1.9 Billion SEK | 99.681% |
| Cantargia AB (publ) | 223.71 Million SEK | 97.284% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | 59.13% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | 79.859% |
| Genovis AB (publ.) | 288.85 Million SEK | 97.896% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 92.87% |
| Mendus AB (publ) | 755.95 Million SEK | 99.196% |
| Kancera AB (publ) | 65.64 Million SEK | 90.742% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 99.517% |
| LIDDS AB (publ) | 17.65 Million SEK | 65.579% |
| Lipum AB (publ) | 12.11 Million SEK | 49.818% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | 81.915% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 97.82% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | 69.677% |
| NextCell Pharma AB | 81.28 Million SEK | 92.524% |
| OncoZenge AB (publ) | 20.34 Million SEK | 70.123% |
| Saniona AB (publ) | 64.14 Million SEK | 90.526% |
| Simris Alg AB (publ) | 174.55 Million SEK | 96.519% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 98.775% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 99.07% |
| Xintela AB (publ) | 18.39 Million SEK | 66.964% |
| Ziccum AB (publ) | 14.97 Million SEK | 59.411% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 95.678% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 99.206% |
| CombiGene AB (publ) | 120.61 Million SEK | 94.962% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 97.2% |
| Intervacc AB (publ) | 259.61 Million SEK | 97.659% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 94.87% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | 90.258% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | 85.517% |
| Corline Biomedical AB | 100.1 Million SEK | 93.929% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 96.569% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | 90.222% |
| Aptahem AB (publ) | 63.02 Million SEK | 90.358% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 98.27% |
| Fluicell AB (publ) | 9.34 Million SEK | 34.936% |
| Biovica International AB (publ) | 131.4 Million SEK | 95.375% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | 88.531% |
| Abliva AB (publ) | 87.49 Million SEK | 93.055% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 99.201% |
| 2cureX AB (publ) | 16.62 Million SEK | 63.447% |
| I-Tech AB | 152.44 Million SEK | 96.014% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 99.403% |
| Cyxone AB (publ) | 43.65 Million SEK | 86.079% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 92.277% |
| Biosergen AB | 7.2 Million SEK | 15.609% |
| Nanologica AB (publ) | 77.42 Million SEK | 92.152% |
| SynAct Pharma AB | 228.01 Million SEK | 97.335% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | 77.293% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 99.566% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | 71.999% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 97.451% |
| Pila Pharma AB (publ) | 8.45 Million SEK | 28.125% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 93.021% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | 78.683% |